BioPharma

Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is...

Argo Biopharmaceutical from China, which happens to be a clinical-stage biotechnology company that’s focused on developing next-generation siRNA therapeutics, has gone on to enter into an additional strategic partnership along with Novartis pertaining to numerous cardiovascular assets that prevail...

LOTTE BIOLOGICS, on September 1, 2025, announced that it has gone on to enter into a late-stage commercial contract manufacturing collaboration along with one of the global biopharmaceutical companies from the US. It is well to be noted that this...

In one of the forward-looking statements published on 14 August 2025, Eli Lilly has reaffirmed its commitment to keeping the country right at the forefront when it comes to biopharmaceutical innovation while advocating for reforms for drug pricing in...

Padcev, which happens to be an antibody drug conjugate that Pfizer has acquired in its $43 billion buyout of Seagen, has gone on to meet the primary objective of a bladder cancer trial, thereby helping people who were ineligible...

The medicine manufacturers from Europe are bracing for President Donald Trump’s plan to slap tariffs of almost 250% on medicine imported from the EU. The declaration made by Trump that the drug exports of Europe will be hit with certain...

The lawmakers in Washington have shared the angst of US drugmakers, which have been surpassed by the fast-progressing biotechnology sector of China, but have not raised any alarms on the recent surge within the licensing deals for medicines that...